EPI-001 NEW
| Price | $30 | $43 | $70 |
| Package | 2mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-07-20 |
Product Details
| Product Name: EPI-001 | CAS No.: 227947-06-0 |
| Purity: 99.67% | Supply Ability: 10g |
| Release date: 2025/07/20 |
Product Introduction
Bioactivity
| Name | EPI-001 |
| Description | EPI-001 is an androgen receptor N-terminal domain antagonist with IC50 of ～6 μM and a selective PPAR-gamma modulator. |
| Cell Research | LNCaP cells are treated with bicalutamide (BIC) or EPI-001 for 1 hr before the addition of R1881 (0.1 nM) for 4 days. LNCaP cells are treated with OCM (50%) with, or without, EPI-001 for 3 days (serum-free, androgen-free, phenol red-free conditions).(Only for Reference) |
| In vitro | EPI-001 blocks transactivation of the AR NTD, interacts with the AF-1 region, inhibits protein-protein interactions with AR, and reduces AR interaction with androgen-response elements on target genes. In LNCaP cells, EPI-001 inhibits both androgen-dependent and androgen-independent (OCM-induced) cell proliferation. [1] In LNCaP cells, EPI-001 also acts as a PPAR-gamma modulator to result in inhibition of androgen receptor expression and activity, which inhibits prostate cancer growth. [2] |
| In vivo | In male mice bearing CRPC LNCaP s.c. xenografts, EPI-001 (50 mg/kg, i.v.) blocks the androgen-axis and inhibits androgen-dependent tumor growth by reducing proliferation and increasing apoptosis. [1] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | H2O : < 1 mg/mL (insoluble or slightly soluble) DMSO : 55 mg/mL (139.28 mM), Sonication is recommended. Ethanol : 70 mg/mL (177.26 mM), Sonication is recommended. |
| Keywords | transactivation | Receptor | PPARγ | PPAR | Peroxisome proliferator-activated receptors | NTD | Inhibitor | inhibit | EPI-001 | domain | Apoptosis | anti-tumor | AndrogenReceptor | Androgen Receptor | Androgen | amino-terminal |
| Inhibitors Related | Stavudine | 5-Fluorouracil | Flubendazole | Cysteamine hydrochloride | Dextran sulfate sodium salt (MW 4500-5500) | Sodium 4-phenylbutyrate | L-Ascorbic acid | Daidzein | L-Glutamic acid | Tributyrin | L-Ascorbic acid sodium salt | Alginic acid |
| Related Compound Libraries | Apoptosis Compound Library | Bioactive Compound Library | ReFRAME Related Library | Anti-Obesity Compound Library | Anti-Breast Cancer Compound Library | Inhibitor Library | Anti-Prostate Cancer Compound Library | Endocrinology-Hormone Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Active Compound Library | Transcription Factor-Targeted Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $931.00/25mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2025-05-02 | |
| $0.00/10mg |
VIP1Y
|
Moxin Chemicals
|
2025-01-16 | |
| $0.00/25kg |
VIP1Y
|
Shaanxi Dideu New Materials Co. Ltd
|
2025-03-08 | |
| $3.00/50kg |
VIP1Y
|
ZHENGZHOU JIUYI TIME NEW MATERIALS CO,.LTD
|
2025-07-28 | |
| $1.00/1KG |
VIP6Y
|
Career Henan Chemical Co
|
2020-01-08 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY